Phenprocoumon is an anticoagulant drug used for the prevention of thrombosis. Coumarin derivative that acts as a long-acting oral anticoagulant.
- Mechanism
- Curator reviewed
Phenprocoumon inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.
- Primary indication
- Used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).Curator reviewed · 5 structured indications
- Formula / weight
- C18H16O3 · 280.3178 g/mol (avg)
- Also known as
- Fenprocumone · Phenprocoumarol · Phenprocoumarole · Phenprocumone
Resolves to
DQDAYGNAKTZFIW-UHFFFAOYSA-NSMILESCCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Phenprocoumon, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account